タケウチ　ツトム   TAKEUCHI Tsutomu   竹内　勤    所属   埼玉医科大学  医学部 学長室    職種   学長
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
掲載誌名	正式名：Rheumatology and Therapy
掲載区分	国外
出版社	Springer Nature
著者・共著者	Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coobms D, Liu J, Anyanwu SI, Lippe R, and Curtis JR.
発行年月	2023/11/20
概要	Introduction This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated with upadacitinib (UPA) or active comparators. Results Median treatment duration ranged from 1.0 to 4.0 years (with a maximum of 6.6 years in RA). Across treatments and indications, rates of malignancy excluding nonmelanoma skin cancer (NMSC) ranged from 0.2 to 1.1, while NMSC ranged from 0.0 to 1.4. In RA, rates of malignancy excluding NMSC were generally similar between UPA15, UPA30, ADA, and MTX (breast and lung cancer were the most common). Conclusion Rates of malignancy excluding NMSC were generally similar between UPA15, UPA30, ADA, and MTX and were consistent across RA, PsA, AS, and nr-axSpA. A dose-dependent increased rate of NMSC was observed with UPA in RA.